Current Clinical Challenges and Strategic Advancements in CAR-T Cell Therapy
DOI:
https://doi.org/10.61173/qxk2pw63Keywords:
CAR-T Cell Therapy, CRS, ICANS, T cell exhaustionAbstract
Chimeric antigen receptor (CAR) T-cell therapy constitutes a paradigm-shifting advancement for treating refractory malignancies, demonstrating unique therapeutic capabilities beyond conventional cancer treatments, which has brought new hope to many patients with advanced cancer. This cellular immunotherapy has achieved unprecedented success in hematologic cancers, yet its extension to solid tumors confronts fundamental biological constraints. Lifethreatening toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity originate from dysregulated immune activation cascades, while T cell exhaustion—characterized by hierarchical epigenetic reprogramming and progressive metabolic failure—severely undermines long-term therapeutic efficacy. These dual limitations demand innovative bioengineering solutions to augment both safety profiles and functional persistence. The present review analyzes core biological mechanisms restricting CAR-T efficacy and surveys cutting-edge approaches designed to circumvent these barriers through integrated genetic reprogramming, metabolic optimization, and microenvironment-responsive receptor engineering. Subsequent discussion focuses on how such multidisciplinary strategies could potentiate cellular immunotherapy’s applicability across diverse oncological contexts, ultimately transforming cancer management paradigms.
References
[1] Giavridis, T. et al. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731–738 (2018).
[2] Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after CD19 CAR-T cell therapy. Cancer Discov. 11, 1402–1419 (2021).
[3] Zhao, R. et al. Mitochondrial metabolic reprogramming in CAR T cells enhances anti-tumor activity. Front. Immunol. 10, 2264 (2019).
[4] Sterner, R.C. & Sterner, R.M. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11, 69 (2022).
[5] Zhang, J. & Wang, L. Manufacturing barriers in CAR-T cell therapy. Blood 141, 1809–1822 (2023).
[6] Hay, K.A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor– modified T-cell therapy. Blood 130, 2295–2306 (2017).
[7] Hay, K.A. et al. Revised Diagnostic Criteria for CRS. Blood 140(Suppl 1), 11–13 (2022).
[8] Gardner, R.A. et al. Predictive Biomarkers for Severe CRS. Nat. Med. 30, 128–138 (2024).
[9] Locke, F.L. et al. Tocilizumab Response in Refractory CRS. J. Immunother. Cancer 11, e006751 (2023).
[10] Abramson, J.S. et al. Anakinra for Steroid-Refractory CRS. Blood Adv. 8, 112–123 (2024).
[11] Sterner, R.C. et al. GM-CSF Neutralization Prevents Severe CRS. Nat. Med. 30, 789–800 (2024).
[12] [Brudno, J.N. et al. Cytosorb® in CAR-T Associated CRS. Transfusion 62, 1529–1538 (2022).
[13] June, C.H. & Sadelain, M. Next-Generation CAR-T Safety Engineering. N. Engl. J. Med. 390, 138–150 (2024).
[14] Santomasso, B.D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958–971 (2018).
[15] Lee, D.W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625– 638 (2019)
[16] Rubin, D.B. et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 80, 109- 118 (2023).
[17] Butt, O.H. et al. Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell–associated neurotoxicity syndrome. JAMA Neurol. 79, 901-910 (2022).
[18] Li, Y. et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Exp. Hematol. Oncol. 11, 90 (2022).
[19] Sterner, R.M. & Sterner, R.C. GM-CSF blockade reduces CAR T-cell induced neurotoxicity through modulation of myeloid cell activation. Blood 143, 621-633 (2024).
[20] Sterner, R.C. et al. Anakinra-embedded CAR-T cells mitigate neurotoxicity without compromising antitumor efficacy. Nat. Biotechnol. 41, 1439-1448 (2023).
[21] Frank, M.J. et al. Oligodendrocyte protection strategies in CAR-T neurotoxicity: From bench to bedside. Sci. Transl. Med. 16, eadg7891 (2024).
[22] Juillerat, A. et al. Hypoxia-regulated CAR-T cells eliminate on-target/off-tumor neurotoxicity. Nature 625, 563-571 (2024).
[23] Saw, J.L. et al. AMPA receptor antagonism terminates CAR-T associated status epilepticus. Neurology 102, e208107 (2024).
[24] Gust, J. & Garden, G.A. CSF matrix metalloproteinase-9 as a predictor of blood-brain barrier disruption severity. Ann. Neurol. 95, 267-279 (2024).
[25] Jenkins, R.W. et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8, 196-214 (2018).
[26] Anderson, A.C. et al. Dual targeting of PD-1 and TIM- 3 reverses T cell exhaustion and overcomes resistance to PD-1 blockade in preclinical models. Sci. Transl. Med. 15, eabq3232 (2023).
[27] Bengsch, B. et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8⁺ T cell exhaustion. Immunity 45, 358- 373 (2016).
[28] Kawalekar, O.U. et al. AMPK activation enhances the antitumor efficacy of CAR T cells by promoting metabolic fitness and memory formation. Mol. Ther. 30, 3156-3171 (2022).
[29] Fraietta, J.A. et al. DNMT3A-edited CAR T cells exhibit enhanced persistence and antitumor activity in neuroblastoma. Blood 141, 1809-1822 (2023).
[30] Juillerat, A. et al. Hypoxia-regulated CAR-T cells eliminate on-target/off-tumor neurotoxicity. Nature 625, 563-571 (2024).
[31] Cherkassky, L. et al. TGFβ-resistant CAR T cells show enhanced metabolic fitness and tumor control. J. Clin. Invest. 133, e167892 (2023).
[32] Thompson, J.C. et al. Circulating exhausted PD-1⁺CD39⁺ CD8⁺ T cells predict resistance to CAR T therapy in lung cancer. J. Clin. Oncol. 42, 1123–1135 (2024).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
